The cooperation between genetic and epigenetic factors in the pathogenesis of Alzheimer's disease
DOI:
https://doi.org/10.33448/rsd-v12i2.38806Keywords:
Alzheimer's disease; Genetics; Epigenetics.Abstract
Aging is an inevitable result of life, characterized by a progressive decline in the function of tissues and organs and an increased risk of mortality. Along with the increase in the elderly population, observed in recent years, there is an increase in the prevalence of neurodegenerative diseases, such as Alzheimer's Disease (AD). The present study consists of an integrative literature review in order to identify the influence of genetic and epigenetic factors in the pathogenesis of AD. The search was carried out during the months of September, October and November 2022, considering studies published in the period between 2014 and 2022, in the following databases: VHL, PubMed MEDLINE, SCIELO, Google Scholar and EbscoHost. It is now very clear that all characteristics of an individual are not determined by DNA alone, but by environment, stress, lifestyle and nutrition that play a vital role in determining an organism's response. In this sense, epigenetic mechanisms involve structural and biochemical changes in chromatin, without alterations in the DNA sequence, which disfigure the expression pattern of genes, affecting several physiological and pathological processes. Therefore, this imbalance in the homeostasis of epigenetic mechanisms is the basis for the abnormal expression of genes related to synaptic plasticity and memory, areas that are notably altered in the initial manifestations of AD. Given the reversible nature of epigenetic mechanisms, these pathways provide promising avenues for therapy against cognitive decline and better prognosis for the disease.
References
Barage, S. H., & Sonawane, K. D. (2015). Hipótese da cascata amiloide: Patogênese e estratégias terapêuticas na doença de Alzheimer. Neuropeptídeos. 52(1), 1-18.
Berson, A., Nativio, R., Berger, S. L., & Bonini, N. M. (2018). Epigenetic Regulation in Neurodegenerative Diseases. Trends In Neurosciences. Elsevier B.V. 41(9), 587-598.
Cheignon, C., Tomas M., Bonnefont-Rousselot, D., Faller, P., Hureau C., & Collin, F. (2017) Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 14(1), 450-464.
Cochran, J. N., Hall A. M., & Roberson, E. D. (2014). The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Res Bull. 103(1), 18-28.
Fenoglio, C., Scarpini, E., Serpente, M., & Galimberi, D. (2018). Role of Genetics and Epigenetics in the Pathogenesis of Alzheimer’s Disease and Frontotemporal Dementia. Journal Of Alzheimer'S Disease. 62(3), 913-932.
Ferreira-Vieira, T. H., Guimaraes, I. M., Silva, F. R., & Ribeiro, R. M (2016). Alzheimer's disease: Targeting the Cholinergic System. Curr Neuropharmacol. 14(1), 101-115.
Gao, X., Qiang, C., Hua, Y., Jie, T., & Zheng, T. (2022). Epigenetics in Alzheimer’s Disease. Frontiers In Aging. Neuroscience. 23(14), 91-106.
Hampel, H., Mesulam, M. M., Cuello, A. C., Farlow, M. M., Giacobini, E., Grossberg, G. T., & Vergallo, A. (2018). The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. Brain. 141(7), 1917-1933.
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015). Immune attack: the role of inflammation in Alzheimer disease. Nature Reviews Neuroscience. 16(6), 358-372.
Huang, F., Weng, M., Liu, R. Wang, J. Z., Schadt, E., Haroutunian, V., Katsel, P., & Wang, X. (2019). CDT2-controlled cell cycle reentry regulates the pathogenesis of Alzheimer's disease. Alzheimers Dement. 15(2), 217-231.
Ittner, A., & Itner, L. M. (2018). Dendritic Tau in Alzheimer's Disease. Neuron. 99(1), 13-27.
Khan, S., Barve, K. H., & Kumar M. S. (2020). Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease. Curr Neuropharmacol. 18(11), 1106-1125.
Kanatsu, K., & Tomita, T. (2017). Molecular mechanisms of the genetic risk factors in pathogenesis of Alzheimer disease. Front Biosci (Landmark Ed). 22(1), 180-192.
Kinney, J. W., Shane, M. B., Murtishaw, A. S., Leisgang, A. M, & Cordeiro, B. T. (2018) Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement. 6(4), 575-590.
Kwakowsky, A., Calvo-Flores, G. B., Govindpani, K., Waldvogel, H. J., & Faull, R. L. (2018). Gamma-aminobutyric acid A receptors in Alzheimer's disease: highly localized remodeling of a complex and diverse signaling pathway. Neural Regen Res. 13(8), 1362-1363.
Liu, X., Jiao, B., & Shen, L. (2018). The Epigenetics of Alzheimer’s Disease: factors and therapeutic implications. Frontiers In Genetics. 9(1), 12-25.
Page, M. J. et al. (2021). The 2020 statement: an updated guideline for reporting systematic reviews . Research Methods and Reporting.
Perkovic, M. N., Paska, A.V., Konjevod, M., Kouter, K., & Pivac, N. (2021). Epigenetics of Alzheimer’s Disease. Biomolecules. 11(2), 195-200.
Rajasekhar, K., & Govindaraju, T. (2018). Perspectiva atual, desafios e perspectivas futuras de intervenções diagnósticas e terapêuticas na doença de Alzheimer. RSC adv. 8(2), 378–380.
Roubroeks, J. A. Y., Smith, R. G., & Lunnon, K. (2017). Epigenetics and DNA methylomic profiling in Alzheimer's disease and other neurodegenerative diseases. Journal Of Neurochemistry. 143(2), 158-170.
Santos, C. M. C.; Pimenta, C. A. M.; & Nobre, M. R. C. (2007). The PICO strategy for the research question construction and evidence search. Revista Latino-Americana de Enfermagem. 15(3),1-7.
Sharma, V. K. Mehta, V., & Singh, T. G. (2020). Alzheimer’s Disorder: epigenetic connection and associated risk factors. Current Neuropharmacology. 18(8), 740-753.
Sen, P., Shah, P. P., Nativio, R., & Berger, S. L. (2016). Epigenetic Mechanisms of Longevity and Aging. Cell. 166(4), 822-839.
Stoccoro, A., & Coppedè, F. (2018). Role of epigenetics in Alzheimer's disease pathogenesis. Neurodegenerative Disease Management. 8(3), 181-193.
Valero, J., Paris, I., & Sierra, P. (2016). Lifestyle Shapes the Dialogue between Environment, Microglia, and Adult Neurogenesis. ACS Chem Neurosci. 7(4), 442-453.
Vakapoulos, C. (2017). Doença de Alzheimer: A Hipótese Serotonérgica Alternativa do Declínio Cognitivo. Jornal da Doença de Alzheimer. 60(3), 859-866.
Zhang, X. X., Tian, Y., Wang, Z. T., Ma, Y. H., Tan, L., & Yu, J. T. (2021). A Epidemiologia dos Fatores de Risco Modificáveis e Prevenção da Doença de Alzheimer. O Jornal de Prevenção da Doença de Alzheimer. 8(3), 313-321.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Gustavo Henrich Pereira Nunes; Maria Fernanda Londe de Lima; Priscila Capelari Orsolin
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
